CMV and TTV virus markers after stem cell transplant
Part of Blood & lymphatic, Infections clinical trials.
This study looks at two viruses (CMV and TTV) in adults who have had a stem cell transplant. It tests how a preventive antiviral medicine (letermovir) affects these viruses over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have had a stem cell transplant (HSCT)
- You or your stem cell donor have had CMV in the past (you are CMV-positive)
- You are getting the antiviral drug letermovir to prevent CMV infection
- You agree to sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
This study looks at how well your immune system fights CMV (a common virus) after you stop taking a preventive medicine called Letermovir. It aims to see if your immune recovery can predict later CMV infections.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation Recipient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.